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Glomerular deposition of complement-control proteins in acute
and chronic glomerulonephritis. Acute poststreptococcal glomer-
ulonephritis (AGN) differed from membranoproliferative glomer-
ulonephritis (MPGN) and lupus nephritis (SLE) in that two of the
proteins that control the C3b-dependent convertase, j3lH and the
C3bC4b-inactivator cofactor (C3bC4bICo), were frequently ab-
sent from the glomerular deposits. In addition, factor B was dis-
tributed with C3 in the capillary walls in hypocomplementemic
AGN patients. From this, it can be assumed that C3bBb is in the
deposits, uninhibited by control proteins as would be predicted
for alternative pathway activation. Factor B could not be found
in normocomplementemic AGN, was rarely present in MPGN,
but was usually present in SLE, most often in the mesangium. In
MPGN and SLE, the control proteins were nearly always pres-
ent in the glomeruli in a distribution like that of C3; in MPGN
they were particularly abundant. Complement profiles indicated
an occasional transient reduction in serum C4 level early in
AGN. Thus, although there is occasional evidence of early clas-
sical activation in AGN, more characteristic is a long period of
alternative activation. Serum levels of control proteins did not
deviate greatly from normal except for reduced serum /31H levels
in MPGN type I.
Dépôts glomerulaires de protéines de contrôle du complement
au cours des glomérulonéphrites aiguës et chroniques. La gloni-
érulonéphrite aigue post streptococcique (AGN) diffère de Ia
glomérulonéphrite membranoproliférative (MPGN) et de la
néphrite lupique (SLE) en ce que deux des protéines qui con-
trôlent Ia convertase C3b dépendante, /31H et le cofacteur macti-
vateur de C3bC4b (C3bC4bICo), sont fréquemment absentes des
dépôts glomerulaires. De plus le facteur B est est distribué
comme le C3 dans les parois capillaires chez les malades atteints
d'AGN hypocomplémentemiques. De cela il peut être déduit
que C3bBb est dans les dépôts, non inhibé par les protéines de
contrôle comme pourrait le laisser prdvoir l'activation par Ia voie
alterne. Le facteur B n'a pas été trouvé dans les AGN normo-
complémentemiques, était rarement present dans les MPGN,
mais était habituellement observe dans Ia SLE, le plus souvent
dans le mesangium. Dans la MPGN et Ia SLE, les protéines de
contrôle étaient presque toujours présentes dans le glomerule
avec une distribution semblable it celle de C3. FlIes étaient par-
ticulièrement abondantes dans la MPGN. Les profils com-
plémentaires indiquaient parfois une diminution transitoire du
C4 sérique précocement dans l'AGN. Ainsi, bien qu'il y ait par-
fois Ia preuve dune activation précoce par Ia voie classique dans
l'AGN, une longue période d'activation par la voie alterne est
plus caractéristique. Les concentrations seriques des protéines
de contrOle ne se sont pas beaucoup écartées des valeurs nor-
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males, une diminution de Ia concentration serique de f3lH dans
Ia MPGN de type I mise a part.
Activators of the alternative pathway of com-
plement foster C3 activation by providing a site for
the formation of the C3b-dependent convertase,
C3bBb, which protects it from inactivation by the
control proteins, /31H, C3bINA, and C3bC4bICo
[1-6]. C3bBb deposited on such a site will cleave
fluid phase C3 to C3b and C3a. Furthermore, C3b,
unchecked by the control proteins, has been found
to bind C5, making it also susceptible to cleavage by
C3bBb, leading to activation of the terminal com-
ponents of the complement pathway [7].
This report describes immunohistochemical stud-
ies of renal biopsy niaterial to detect the proteins
which form C3bBb (C3 and factor B), the control
proteins (/31H, C3bINA, and C3bC4bICo), other
complement components (Clq, C4, C5) and immu-
noglobulins (IgG, 1gM, IgA, and IgE), in acute gb-
merulonephritis (AGN), membranoproliferative
glomerubonephritis (MPGN), and systemic lupus
erythematosus (SLE). In addition, serum concen-
trations of the control proteins and some com-
plement components are reported for these dis-
eases.
Methods
Renal biopsy material was obtained from eight
patients with type I MPGN (subendothelial depos-
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its), four with type II MPGN (dense intramem-
branous deposits), six with type III MPGN (sub-
epithelial and subendothelial deposits with dis-
ruption of the basement membrane) [8], eight with
SLE, and eleven with AGN.
According to the classification of Baldwin et al
[9], the glomerular lesions in six of the SLE patients
were diffuse proliferative; and in two, focal prolifer-
ative.
Six of the eleven patients with AGN were hypo-
complementemic. These six had evidence of post-
streptococcal disease with a history of antecedent
upper respiratory illness and elevation of antistrep-
tolysin (ASO) and streptozyme titers. Biopsies in
this group were performed within 2 weeks of onset
of nephritis in five and 5 weeks after onset in the
sixth patient. All were hypocomplementemic at the
time of biopsy. The five normocomplementemic
patients with AGN had a disease similar in clinical
course to that of the hypocomplementemic patients.
All had a history of antecedent respiratory infection,
and all had ASO titers of 1:250 or more and/or
streptozyme titers of 1:500 or greater. Four had
biopsies within 3 weeks of the onset of nephritic
symptoms and had complement levels determined
prior to biopsy. The fifth was biopsied 5 weeks
after onset of nephritis and did not have complement
levels determined until the time of biopsy. All five
patients eventually had resolution of hematuria and
proteinuria.
The methods of preparation and examination of
tissue obtained by percutaneous biopsy have been
described previously [10].
Preparation of antisera and labeling. J31H con-
tained in a 4% PEG precipitate of normal serum was
applied to a Sephadex QAE-50 column. Those frac-
tions containing f31H were pooled, concentrated,
and applied to a BioRex 70 column, and /3lH was
eluted in early fractions of the gradient at which
conductivity was 11.5. Antiserum raised in a goat
was found to be monospecific and showed a reaction
of complete identity with Dr. Ruddy's' anti-131H.
The specificity of the antiserum for f3lH was further
demonstrated by immunoadsorption experiments.
The IgG fraction of the anti-f3lH was coupled to
cyanogen-bromide-activated Sepharose 4B [11]
and used in the presence of EDTA to deplete normal
serum of f31H. C3, factor B, C3bC4bICo, and
C3bINA remained in normal concentrations. When
magnesium was added to the /31H-depleted EDTA
serum, very rapid spontaneous breakdown of C3
and factor B occurred, as evidenced by rapid loss
of the B antigenic determinant of C3 [12] and con-
version of factor B. This phenomenon has been
described previously [13].
Antibody to C3bC4bICo was found as the single
contaminant in a crude preparation of anti-IgM. The
antiserum was made monospecific by absorption
with serum from a patient with Waldenstrom's
macroglobulinemia. The anti-C3bC4bICo showed
complete identity with Dr. Shroud's1 antibody to
C3bC4bICo as well as Dr. Nussen's' antibody to
the C4-binding protein [14]. Anti-C3bC4bICo
(Shroud) also showed complete identity with anti-
C4-binding protein. The evidence for the specificity
of the anti-C3bINA used in this study has been
given previously [15].
Development of the immunoelectrophoretic pat-
tern of normal serum using anti-/31H, anti-C3bINA,
and anti-C3bC4bICo separately or in mixture result-
ed in three arcs of/3 mobility which did not identify
with each other.
Preparation of monospecific antisera to the re-
maining complement proteins has been described
previously [16]. Two preparations of antifactor B
were used for immunofluorescence. One was reac-
tive only with the Bb fragment, whereas the other
was reactive with both Bb and Ba [17].
Antiserum to IgE was absorbed with normal hu-
man serum containing IgE in low concentration to
remove light-chain specificity.
The TgG fraction of the antiserum to IgG, IgA,
1gM, IgE, C4, C3, CS, factor B, 131H, C4bC3bICo,
and C3bINA was labeled directly with fluorescein
isothiocyanate as described by Kawamura [18].
Serum levels of complement components. By
radial immunodiffusion (RID), levels of Clq, C4,
C3, CS, factor B, f31H, C3bINA, and C3bC4bICo
were measured in serum specimens from 50 normal
adults and 53 patients. Specimens were either
stored at —70° C or used fresh. Antiserum to C3
was monospecific for the A determinant of C3 [12],
and, when used for RID, the diameter of the precip-
itin rings was unaffected by the conversion of C3
occurring when serum ages [15]. The concentra-
tions of these proteins are reported for serum speci-
mens from 10 patients with MPGN type I, 7 with
type II, 11 with type III, 18 with hypocomplemen-
temic AGN, and 7 with SLE. Complement profiles
are reported only for specimens with serum C3 con-
centration <60 mg/dl (normal range, 90 to 200 mg/
dl). Only one specimen per patient is reported.
Statistical analysis of the data was done with Stu-
dent's t test.
See Acknowledgments.
Complement-control proteins in glomerular deposits 507
Table 1. Results of immunohistologic studies to detect complement components, control proteins, and immunoglobulins in the glomeruli
in the various nephritidesa
Clq C4 C3 CS Factor B /31H C3bC4bICo C3bINA IgG 1gM IgA IgE
AGN
C3 2/6 0/4 6/6 4/4 5/6 1/6 0/4 0/3 4/6 1/6 1/6 2/6
NormalC3 0/4 0/4 5/5 3/4 0/5 1/5 0/4 0/1 4/5 0/5 1/5 3/4
MPGN
Type I 7/8 6/8 8/8 7/7 1/8 8/8 8/8 0/5 8/8 7/8 0/8 7/7
Type II 4/4 1/3 4/4 3/3 0/4 4/4 3/3 0/3 2/4 3/4 0/4 2/3
Type III 3/6 0/5 6/6 5/5 0/6 6/6 2/5 0/6 3/6 3/6 4/6 0/6
SLE 8/8 8/8 8/8 8/8 6/8 8/8 8/8 0/5 8/8 8/8 8/8 5/8
a Numerator denotes number of biopsies (patients) with protein present; the denominator, number of biopsies examined.
Results
Immunofluorescence. The results of immuno-
histologic study of renal biopsy material are shown
in Table 1. In AGN, C3 was found in the capillary
loop deposits of all patients, but factor B was pres-
ent in only 5 of the 11, all of whom were hypo-
complementemic. The pattern of fluorescence with
anti-factor B is shown in Fig. 1. These deposits fluo-
resced with either preparation of antisera to factor
B, giving evidence that they contained the larger
fragment, Bb. Clq was present in 2 of 10 (20%), and
C4 was absent in all. The control proteins, /31H, and
C3bC4bICo, were usually absent, and when pres-
ent, intensity of fluorescence was minimal. In no
disease was C3bINA found.
The immunofluorescent pattern in MPGN dif-
fered in several respects from that in AGN. Factor
B was generally absent; in one patient it was pres-
ent in small amounts in loop deposits. /31H, how-
ever, was abundant in the capillary loops in a distri-
bution identical to that of C3 (Fig. 2). In patients
with types I and II MPGN, the C3bC4bICo was
likewise abundant and distributed like C3 (Fig. 3). It
was absent in 3 of 5 with type III.
The pattern in SLE was also distinctive. The
early complement components, Clq and C4, as well
as the control proteins, were universally present.
The control proteins were, however, less abundant
than they were in MPGN. Deposits containing fac-
tor B were found in 6 of 8 patients. More details of
Fig. 1. Discrete deposits labeled with antibody to factor B in a glomerulus from a patient with hypocomplementemic AGN.
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Fig. 2. Capillary loop label (fringe type) with antibody to /3/H in
a glomerulus from a patient with MPGN.
the immunohistologic results in SLE and their rela-
tion to the histologic type are given in Table 2. In 2
of 6 patients with diffuse proliferative lesions and in
both with focal proliferative, factor B distribution
differed from that in AGN in that it was present only
in the mesangium (Fig. 4). In all these, C3 and IgG
were also present in the mesangium. In 2 others
with diffuse lesions, Factor B was found only in the
capillary loops in an interupted linear pattern. IgG
and C3 was also found in the capillary ioops in these
patients but in a granular pattern.
Serum levels of complement proteins. In Table 3,
the mean values and standard deviations for the
serum concentrations of Clq, C4, C3, factor B,
f3lH, C3bINA, and C3bC4bICo are shown for 53
patients with various nephritides.
Marked reduction of Clq and C4 was seen only in
SLE. In type I MPGN, the mean levels of these
proteins were significantly lower than those for nor-
mal subjects but in only 4 patients were the values
below the lower limit of the normal range. In AGN,
Clq was in normal concentration and the mean con-
centration of C4 was decreased; levels of C4 below
the lower limit of normal were found in 6 of 18 pa-
tients.
C5 was markedly reduced in AGN and in types I
and III MPGN but only slight reductions were seen
in SLE and MPGN type II.
Fig. 3. Capillary loop label (predominantly fringe type) with anti-
body to G3bC4bICO in a glomerulus from a patient with MPGN.
As reported previously [15], factor B was low in
all the nephritides except AGN.
The levels of the control proteins were not greatly
depressed in any of the nephritides. The most
marked change was a reduction of /31 H in type-I
MPGN. Levels were normal in SLE and only slight-
ly reduced in MPGN types II and III. Only minor
changes were seen in the levels of C3bINA, and in
no disease was the C3bC4bICo in low concentra-
tion. Elevated levels of the C3bINA in AGN have
been noted previously [15].
Discussion
/31H has been found to be an essential control
protein for the C3b feedback cycle [1, 2]. When
f31H displaces factor B from C3bBb, the resulting
complex, C3b/31H, is incapable of cleaving native
C3 [19]. C3b/31H then interacts with C3bINA and
C3bC4bICo to form C3b' which is broken down to
C3c and C3d by serum proteases [6]. C3bINA and
C3bC4bICo are also control proteins for the classi-
cal pathway convertase C4b2a [6, 20].
The present observations on AGN support the
concept that early in the disease, circulating im-
mune complexes activating the classical pathway
are present [21-23]. As in one-shot serum sickness
in the rabbit [24], IgG may be present in capillary
wall deposits, and in a minority of patients, serum
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Fig. 4. Mesangial label with antibody to factor B in a glomerulus from a patient with SLE.
C4 levels are transiently depressed; Clq levels are
rarely low. Others have noted these peculiarities in
the complement profile [25-28], and a role for im-
mune complexes in pathogenesis is widely held [21-
23]. In contrast to the behavior of C4 and Clq, C3
levels are reduced in 90% of the patients, and the
depression lasts for as long as 8 weeks [10, 28, 29].
The long-standing C3 depression in the face of ab-
sent or transient depression of C4 and Clq has not
been explained fully.
The present immunohistologic studies provide
evidence that the continuing depression of the C3
level in AGN may be through the alternative path-
way. Of the eleven patients with AGN on whom





IgG C3 B /31H C3bC4bICo
Diffuse proliferative glomerulonephritis
I C,M C,M C C C,M
2 M M M M M
3 C,M C,M — C,M C,M
4 C C — C C
5 C,M C,M M M M
6 C,M C,M C C
Focal proliferative glomerulonephritis
M
7 M M M M M
8 M M M M M
Abbreviations are C, capillary loop; M, mesangial; —, nega-
tive.
biopsy material was available, the glomerular de-
posits were devoid of f31H in nine, and it was pres-
ent in scanty amounts in two. C3bC4bICo was ab-
sent in all eight tested. The observations make
AGN unique among the nephritides and suggest
that the C3 present in the deposits is, or has been, in
a privileged site inaccessible to inactivation by the
control proteins. That at least some of the C3 in the
deposits is in the form of convertase, C3bBb, is sug-
gested by the labeling of the loop deposits produced
by antiserum to factor B. Factor B is not known to
bind to any protein other than C3b and C3 nephritic
factor (C3NeF) [30], so that the similar distribution
of factor B and C3 would indicate that active C3bBb
is present in the capillary loops. The data not only
give evidence that alternative pathway activation
has occurred but also that it is the cause of the
hypocomplementemia in these patients; factor B
was not found in the glomerular deposits of the nor-
mocomplementic patients with AGN. Factor B, on
a few occasions only [3 1-33], has been reported to
be a constituent of the glomerular deposits in hu-
man glomerulonephritides, although it is found in
the pentubular deposits in experimental tubulo-
interstitial disease in guinea pigs [34].
Further evidence for alternative pathway activa-
tion in AGN is the absence of C4 in the glomerular
deposits, indicating the absence of the classical
pathway convertase C4b2a. The Clq in the deposits
of two of the ten AGN patients may represent depo-
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Table 3. Serum concentrations of complement and control proteinsa
Normal adults AGN SLE MPGN I MPGN II MPGN III
(50) (18) (7) (10) (7) (11)
Clq, UldI 118.0 121.0 20.0 106.0 118.0 113.0
1 SD 12.5 30.3 31.8 23.2 14.5 25.4
P — — <0.005 <0.025 — —
C4, ng/d1 50.9 35.8 3.8 34.4 61.8 52.0
I SD 13.5 20.7 1.7 18.3 22.1 24.6
P — <0.005 <0.005 <0.005 — —
C3,mgldl 141.2 22.9 35.9 24.9 32.7 34.5
1 SD 14.9 13.3 13.0 17.1 14.5 17.2
P — <0.005 <0.005 <0.005 <0.005 <0.005
C5,mg/dl 6.4 2.6 4.8 2.7 5.2 3.3
1SD 1.3 1.3 1.4 1.6 1.3 2.1
P — <0.005 <0.01 <0.005 <0.05 <0.005
FactorB,,ng/dl 24.1 26.0 14.3 18.9 14.6 15.7
I SD 4.7 6.8 7.1 4.4 4.6 4.7
P — — <0.005 <0.005 <0.005 <0.005
C3bINA, %normal 100.0 120.0 109.0 101.0 85.0 89.0
1 SD 16.9 18.0 24.0 14.4 17.2 9.9
P — — — — <0.025 <0.05
f3lH,%normal 100.0 102.0 93.0 77.0 85.0 92.0
I SD 13.7 14.5 19.0 21.6 16.8 16.9
P — — — <0.005 <0.01 —
C3bC4bICo, %normal 100.0 110.0 100.0 95.0 93.0 105.0
1 SD 14.0 13.7 17.4 13.6 14.4 28.2
P — — — — — —
a P values are given only for means significantly low. Numbers in parentheses denote numbers of patients.
sition in response to tissue injury or could be the
residual of earlier classical pathway activation.
Thus, in hypocomplementemic AGN, the present
observations suggest that active C3bBb is present in
the glomerular deposits. Whether the convertase is
assembled on circulating complement reactive ma-
terial, which is unique in that it restricts access of
the control proteins, or whether an alteration in the
basement membrane material favors an alternative
pathway reaction is not at present clear. Others [35]
have shown that disruption of sialic acid residues by
neuraminidase will provide privileged sites on
sheep red blood cells for C3bBb, making it in-
accessible to f31H. The group A streptococcus has
been shown to produce neuraminidase [36].
In marked contrast to AGN, /31H was present in
the deposits in all patients with MPGN and lupus
nephritis, and C3bC4bICo was also present in high
frequency, being absent in only three patients with
MPGN type III. These proteins, like C3, were most
abundant in the capillary loops but were also pres-
ent in mesangial deposits.
The significance of the presence of factor B in the
glomerular deposits of six of the eight patients with
lupus nephritis is not clear. In two, it was found in
the capillary ioops, as in AGN; and in four, in the
mesangium. The presence of C3bBb could be in-
ferred since C3 appeared to be deposited with factor
B. The presence of C3bBb might be correlated with
the observation that the control proteins were not
as abundant in the deposits in lupus as they were in
MPGN, thus giving evidence that a moiety of the
complement activation in lupus may be by the alter-
native pathway. Circulating material sedimenting at
19S and activating complement in a magnesium-de-
pendent reaction has been observed in the serum of
patients with lupus [37, 38].
The consistent absence of glomerular C3bINA
would indicate that this protein either does not bind
or is only transiently bound, yet it is known to be
essential for convertase inactivation [35].
Marked changes in the levels of the control pro-
teins do not occur in the hypocomplementic nephri-
tides. The somewhat elevated C3bINA in the acute
nephritics may again be the result of an acute phase
reaction [15]. The mean serum f31H concentration
was significantly depressed in MPGN, and for type
I it was nearly two standard deviations below the
normal mean. Moderately reduced serum [31H lev-
els in MPGN have been noted by others [39]. The
reason for the low levels is unclear but could reflect
removal via circulating complexes or possibly de-
pressed synthesis of J31H. The level of C3bC4bICo
was not reduced in any disease.
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